153 related articles for article (PubMed ID: 1988519)
1. Comparison of functional activities between IgG1 and IgM class-switched human monoclonal antibodies reactive with group B streptococci or Escherichia coli K1.
Raff HV; Bradley C; Brady W; Donaldson K; Lipsich L; Maloney G; Shuford W; Walls M; Ward P; Wolff E
J Infect Dis; 1991 Feb; 163(2):346-54. PubMed ID: 1988519
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the opsonic and complement triggering activity of human monoclonal IgG1 and IgM antibody against group B streptococci.
Shyur SD; Raff HV; Bohnsack JF; Kelsey DK; Hill HR
J Immunol; 1992 Mar; 148(6):1879-84. PubMed ID: 1541826
[TBL] [Abstract][Full Text] [Related]
3. Functional activities of monoclonal antibodies to the O side chain of Escherichia coli lipopolysaccharides in vitro and in vivo.
Kim KS; Kang JH; Cross AS; Kaufman B; Zollinger W; Sadoff J
J Infect Dis; 1988 Jan; 157(1):47-53. PubMed ID: 2447199
[TBL] [Abstract][Full Text] [Related]
4. Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity.
Oishi K; Koles NL; Guelde G; Pollack M
J Infect Dis; 1992 Jan; 165(1):34-45. PubMed ID: 1727896
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies reactive with K1-encapsulated Escherichia coli lipopolysaccharide are opsonic and protect mice against lethal challenge.
Kaufman BM; Cross AS; Futrovsky SL; Sidberry HF; Sadoff JC
Infect Immun; 1986 May; 52(2):617-9. PubMed ID: 3516883
[TBL] [Abstract][Full Text] [Related]
6. Absolute requirement for complement in monoclonal IgM antibody-mediated protection against experimental infection with type III group B streptococci.
Shigeoka AO; Jensen CL; Pincus SH; Hill HR
J Infect Dis; 1984 Jul; 150(1):63-70. PubMed ID: 6379061
[TBL] [Abstract][Full Text] [Related]
7. Human monoclonal antibody homodimers. Effect of valency on in vitro and in vivo antibacterial activity.
Wolff EA; Esselstyn J; Maloney G; Raff HV
J Immunol; 1992 Apr; 148(8):2469-74. PubMed ID: 1560202
[TBL] [Abstract][Full Text] [Related]
8. Opsonic activity of human IgG and IgM antibody for type III group B streptococci.
Anthony BF; Concepcion NF
Pediatr Res; 1989 Oct; 26(4):383-7. PubMed ID: 2677951
[TBL] [Abstract][Full Text] [Related]
9. Complement activating and opsonic capacity of monoclonal antibodies raised against Escherichia coli O111 and its rough mutant J5.
Vreede RW; Leuvenink J; Bouter AS; Brouwer EC; Marcelis JH; Verhoef J
Eur J Clin Microbiol; 1986 Apr; 5(2):141-7. PubMed ID: 3522225
[TBL] [Abstract][Full Text] [Related]
10. Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide.
Pollack M; Koles NL; Preston MJ; Brown BJ; Pier GB
Infect Immun; 1995 Nov; 63(11):4481-8. PubMed ID: 7591089
[TBL] [Abstract][Full Text] [Related]
11. Minimal concentration of human IgM and IgG antibodies necessary to protect mice from challenges with live O6 Escherichia coli.
Massironi SM; Arslanian C; Carneiro-Sampaio MM; Pontes GN
FEMS Immunol Med Microbiol; 2011 Nov; 63(2):193-201. PubMed ID: 22077222
[TBL] [Abstract][Full Text] [Related]
12. Human IgG but not IgM antibodies can protect mice from the challenge with live O6 Escherichia coli.
Pontes GN; Massironi SG; Arslanian C; Palmeira P; Carneiro-Sampaio MM; Nagao AT
Scand J Immunol; 2005 Oct; 62(4):353-60. PubMed ID: 16253122
[TBL] [Abstract][Full Text] [Related]
13. Human monoclonal antibody with protective activity for Escherichia coli K1 and Neisseria meningitidis group B infections.
Raff HV; Devereux D; Shuford W; Abbott-Brown D; Maloney G
J Infect Dis; 1988 Jan; 157(1):118-26. PubMed ID: 3121759
[TBL] [Abstract][Full Text] [Related]
14. Effect of light chain V region duplication on IgG oligomerization and in vivo efficacy.
Shuford W; Raff HV; Finley JW; Esselstyn J; Harris LJ
Science; 1991 May; 252(5006):724-7. PubMed ID: 1902593
[TBL] [Abstract][Full Text] [Related]
15. Type-specific monoclonal antibody enhances the local phagocytic response to group B streptococcal infection.
Shigeoka AO; Weber ME; Pincus SH; Pritchard DG; Egan ML; Hill HR
J Infect Dis; 1986 Jun; 153(6):1170-3. PubMed ID: 3517190
[No Abstract] [Full Text] [Related]
16. Fibronectin enhances the opsonic and protective activity of monoclonal and polyclonal antibody against group B streptococci.
Hill HR; Shigeoka AO; Augustine NH; Pritchard D; Lundblad JL; Schwartz RS
J Exp Med; 1984 Jun; 159(6):1618-28. PubMed ID: 6374010
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of immunotherapeutic approaches for the potential treatment of infections caused by K1-positive Escherichia coli.
Cross AS; Zollinger W; Mandrell R; Gemski P; Sadoff J
J Infect Dis; 1983 Jan; 147(1):68-76. PubMed ID: 6401788
[TBL] [Abstract][Full Text] [Related]
18. Opsonic and protective activity of immunoglobulin, modified immunoglobulin, and serum against neonatal Escherichia coli K1 infection.
Bortolussi R; Fischer GW
Pediatr Res; 1986 Feb; 20(2):175-8. PubMed ID: 3511443
[TBL] [Abstract][Full Text] [Related]
19. Immunologic regulation of E. coli K1 by serum from neonatal rats is enhanced following intraperitoneal administration of human IgG.
Lassiter HA; Christensen RD; Parker CJ
J Infect Dis; 1989 Mar; 159(3):518-25. PubMed ID: 2644382
[TBL] [Abstract][Full Text] [Related]
20. Characterisation and protective capacity of monoclonal antibodies elicited in mice against protein epitopes of antibiotic-exposed Escherichia coli.
Lun MT; Raponi G; Amatucci AM; Natali PG; Fraioli R; Mancini C
J Med Microbiol; 1997 Feb; 46(2):122-8. PubMed ID: 9060871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
